Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alpharma Submits Embeda Abuse-Deterrent Morphine Capsule To FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Company files NDA slightly ahead of potential competitor Remoxy, in development by Pain Therapeutics.
Advertisement

Related Content

King Makes Play For Alpharma To Build Specialty Pain Franchise
King Makes Play For Alpharma To Build Specialty Pain Franchise
Alpharma Withdraws Embeda NDA
Alpharma Withdraws Embeda NDA
Pain Therapeutics’ Remoxy Steps Forward
Pain Therapeutics’ Remoxy Steps Forward
Alpharma’s Flector NSAID Patch Off To A Strong Start, CEO Says
Alpharma’s Flector NSAID Patch Off To A Strong Start, CEO Says
Alpharma To Launch First Topical NSAID Patch Flector In January
Remoxy NDA Set For Q2 Following Positive Phase III Results

Topics

Advertisement
UsernamePublicRestriction

Register

PS067496

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel